Hospitals & Asylums
DonÕt Forget to Try Atropine and Pralidoxime Chloride Injection for Emergency Stroke Treatment HA-30-1-17
By Anthony J. Sanders
Three
quarters of a million Americans suffer a cerebral vascular accident (CVA), also
known as a stroke, each year. One-fifth of them die of the stroke, and at least
one-third remain permanently disabled (Bradley Õ09:
62, 63). Stroke ranks as the number four most common cause of death (behind
heart disease, cancer and chronic lower respiratory disease) but number one as
the cause of disability and a contributor to dementia. Cerebral vascular
disease costs the U.S. health care system an estimated $60 billion each year.
Stroke symptoms include a sudden numbness or weakness of the face, arm or leg
(especially on one side of the body), sudden confusion or difficulty
understanding speech, sudden loss of the ability to speak, sudden trouble
seeing in one or both eyes, sudden trouble walking, dizziness, or loss of
balance or coordination or a sudden severe headache with no known cause. A stroke is a sudden
loss of function of part of the brain. Usually the cause is either (1) ischemic
stroke; sudden loss of blood flow to part of the brain because an artery
that supplies blood to that part of the brain has become blocked (ischemia) due
to atherosclerosis, in 87 percent of strokes or (2) hemorrhagic stroke;
bleeding (hemorrhage) into the brain because an artery has burst, due to high
blood pressure in 7-10 percent of cases. In about 15 percent of individuals who
come to an emergency room with the sudden onset of a brain disorder, the cause
of stroke turns out to be an epileptic seizure followed by weakness on one
side, or something else such as a brain tumor, low blood sugar (hypoglycemia),
an abscess in the brain, a blood clot over the surface of the brain caused by
head trauma, or some other condition (Spence Õ06: 3). The risk increases with age: nearly three-quarters of strokes occur
after age 65, with the risk more than doubling each decade after age of 55. In
the United States, strokes increase in a given year from 35 per 100,000 people
at age thirty-five to 1,100 to 100,000 at ages seventy-five to eighty. Getting treatment for an ischemic stroke within three
hours of the onset of symptoms with tissue plasminogen activator (tPA) can dissolve clots and lessen disability by 40 percent
if it is administered within three hours of an ischemic stroke. A hemorrhagic
stroke caused when a blood vessel breaks and bleeds into the brain is much
harder to treat: more than half are fatal. rtPA, a clot-busting drug, is not for home use
because it would increase hemorrhaging and a physician must distinguish between
ischemic and hemorrhagic stroke. Extensive physical therapy for many months
helps many regain function (Horstman Õ12: 70, 72). rtPA (recombinant tissue
plasminogen activator) is for mild strokes only <25 on the NIH stroke scale,
in patients age <80, without hemorrhage, anticoagulant use or elevated blood
pressure (Hazinsky '10: 18-19). It is proposed to
introduce atropine or other effective anticholinergic drug for administration
by emergency medical technicians and emergency room doctors to neutralize the
effect of the lucid dreaming pill galamantine, that
cause the side-effect of sleep paralysis that cannot be ignored as a stroke
risk, in both ischemic and hemorrhagic strokes with Atropine IV or by
endotracheal tube IO (LaBerge '03).
Atropine and
pralidoxime (DuoDote¨) is
indicated for the treatment of poisoning by organophosphorous
nerve agents as well as organophosphorous
insecticides. Atropine and pralidoxime (DuoDote) is injected into a muscle in the upper thigh - Atropine 2.1 mg/0.7 mL Pralidoxime Chloride 600 mg/2 mL.
One injection should be enough for the emergency treatment of a stroke patient
of undetermined cause. A healthcare provider will
administer this injection. The combination of atropine and pralidoxime
is used as an antidote to treat poisoning by a pesticide (insect spray) or a
chemical that interferes with the central nervous system, such as nerve gas or galamantine. Atropine competitively blocks the effects of
acetylcholine, including excess acetylcholine due to organophosphorous
poisoning, at muscarinic cholinergic receptors on smooth muscle, cardiac
muscle, and secretory gland cells and in peripheral autonomic ganglia and the
central nervous system. Pralidoxime
reactivates acetylcholinesterase which has been inactivated by phosphorylation due to an organophosphorous nerve agent or insecticide. Reactivated acetylcholinesterase hydrolyzes excess acetylcholine
resulting from organophosphorous poisoning to help
restore impaired cholinergic neural function. When atropine and pralidoxime are used together, pralidoxime
may potentiate the effect of atropine. When used in combination, signs of atropinization (flushing, mydriasis,
tachycardia, dryness of the mouth and nose) may occur earlier than might be
expected when atropine is used alone.
Breathing,
blood pressure, oxygen levels, kidney function, and other vital signs will be
watched closely. After treatment with atropine and pralidoxime,
you may be watched for up to 72 hours. Some of the side effects of atropine and
pralidoxime may be similar to the symptoms of
poisoning. Avoid becoming overheated or dehydrated during exercise and in hot
weather. Atropine can decrease sweating and you may be more prone to heat
stroke for a short time after receiving this medication. Overdose may occur if
the patient receive satropine and pralidoxime
but has not actually been exposed to the specific poisons this medication is
designed to treat. Symptoms may include vision problems, feeling unsteady, loss
of balance or coordination, trouble concentrating, fast heart rate, confusion,
hallucinations (seeing or hearing things), decreased sweating, hot and dry
skin, fainting, weak or shallow breathing, or breathing that stops after
receiving atropine and pralidoxime injection (DuoDote). In a study of organophosphate poisonings one
patient is reported recovered from their cerebral hemmorrhage
(Quinby '64: 28). Atropine should be
included in the emergency medical response to all strokes, both
hemorrhagic and ischemic strokes. Further review of galamantine is needed because the lucid dreaming patent
application of
2003 found there was also associated with a significantly elevated frequency of sleep paralysis. Sleep paralysis is a parasoma that can be very nightmarish. Essentially,
one remains aware during the transition into sleep onset and/or REM sleep while
the body undergoes muscle paralysis (LaBerge
'03). Drugs with anticholinergic properties and which cross the
blood/brain barrier, such as atropine, benztropine (Cogentin) and trihexyphenidyl (Artane) counteract the effects of galantamine (Toro '07).
Dreams
are a controversial subject among sleep researchers. Virtually everyone
dreams every night, three, four, or five times a night in 5 to 45 minute
discrete episodes. Drug use, prior sleep patterns,medical illness and other factors may alter the
length, frequency and time of occurrence of dreams, but a truly dreamless sleep
is unusual. Most people will have four or five dream, or REM periods each night
during which one or more dreams will occur. REM stands for the rapid eye
movement that occurs in dreaming sleep. We only remember dreams, however
if we awaken during the dream or shortly thereafter. Thus, people who
sleep soundly through their REM periods will have little or no dream
recall. Most people find even casual analysis of their dreams helpful in
understanding themselves and solving problems of everyday life. Stories
of dreamers solving important problems in dreams are widely reported.
August Kekule, an eighteenth
century chemist, discovered the structure of benzene during a dream.
Mikhail Tal, a former world chess champion, describes in his autobiography solving
a difficult chess problem this same way. Lucid dreams are those in which
the dreamer can control the action as if awake. Recurrent dreams usually reveal
psychological issues that are interesting for the individual to ponder.
When entering the state of
sleep in which we dream, our muscles become
paralyzed. The paralysis is very real, it
protects us from acting out dreams when we sleep. Even though we are asleep, we
may have some awareness of this paralysis, which may cause our minds to create
dreams in which we are trapped and unable to escape, one of the most common
themes in recurrent dreams (Kavey '95: 33-35).
ÒOneirogensÓ (from the Greek oneiros
meaning ÒdreamÓ and gen meaning ÒcreatingÓ), which produce and also
enhance dream-like states of consciousness. These herbs and roots have been
used for thousands of years for prophetic divination through dreams,
out-of-body experiences, and to consciously awaken during dream states. Oneirogens represent only one specific class of entheogens that can be exclusively used for lucid
dreaming. The following legal psychedelics can be safely consumed having
minimal effect on waking consciousness, and will only exhibit their effects
when you fall into a natural state of sleep. Calea
zacatechichi (Mexican Dream Herb), Artemisa vulgaris (Mugwort)
contraindicated for use during pregnancy, Heimia salicifolia (Sun Opener), Celastrus
paniculatus (Intellect Tree), Silene
capensis (Zhosa Dream
Root), Nymphaea caerulea
(Blue Lotus), Asparagus racemosus (Tian Men Dong) adaptogenic, and Entada reheedii (African Dream
Bean) (Sol '17). Galantamine has emerged as the lucid
dreaming pill after being patented by LaBerge, S.
Substances that enhance recall and lucidity during dreaming, United States
Patent Application 604138 (LaBerge '03) in
2004. Galantamine is found in the natural world
in many plant sources, including the common daffodil (Narcissus pseudonarcissus). Today, it is used commercially as an
extract derived from red spider lily (Lycoris radiata), the Golden spider lily (Lycoris
aurea) or from the Snowdrop plant (Galanthus nivalis). The resulting
compound is
galanthamine hydrobromide.
Galantamine and its derivatives was
approved by the FDA in 2001, and is largely used as a memory-improvement
supplement for sufferers of Alzheimers disease and mild
dementia. Only recently has the substance been used as an oneirogen, or a dream enhancing
supplement. Galantamine keeps acetylcholinesterase from breaking down acetylcholine,
temporarily leading to increased memory function, dream recall and
lucidity. As early as 1975, dream researchers found out that
acetylcholine and its inhibitors are somehow involved with dream sleep (Amatruda et al '75). High acetylcholine
levels in the brain was associated with the prevention of memory loss,
which is why it appears to be effective in treating Alzheimers.
The compound acts immediately to increase the duration of REM sleep, and the
dream state is made more structurally sound (Riemann et al '94).
There
Òwas also associated with a significantly elevated frequency of sleep paralysis
and a 40% increase in estimated time awake during the nightÓ. Sleep
paralysis is a parasoma that can be very nightmarish.
Essentially, one remains aware during the transition into sleep onset and/or
REM sleep while the body undergoes muscle paralysis (LaBerge
'03). Drugs with anticholinergic properties and which cross the
blood/brain barrier, such as atropine, benztropine
(Cogentin), trihexyphenidyl (Artane),
and perhaps
amantadine (Symmetrel)
counteract the effects of galantamine. Also, the
following medical issues have been documented to be irritated or worsened by
the use of galantamine: asthma, lung diseases,
epilepsy or history of seizures, heart problems, including slow heartbeat or
heart murmur, kidney and/or liver problems, stomach ulcer, and urinary tract problems.
Taken orally, the galantamine supplement is active
and at full strength within an hour of ingestion. The half-life is about 7 hours.
Recommended dosage for dream enhancement is on the low
side: 4 – 8 mg. (AlzheimerÕs patients, on the other hand, often take 12mg
or more a day) (Toro '07). Sleep paralysis however poses at least a moderate
stroke risk that consumer must be informed of. There seems to be a
correlation between the patenting of galantamine and
an epidemic of involuntary exposure to what is presumed to be galantamine associated lucid dreaming in geographically
diverse family members of a higher education applicant resulting in strokes in
the frailest and most elderly of that applicants' family members and perplexing
lucid dreaming in others. Lucid dreams are traditionally considered a bad
omen. There is reason for the patent holder to believe that galantamine
and, to a lesser or greater extent, other oneirogenic
herbs and entheogens pose a stroke risk that requires
review (LaBerge '03).
The
most common identified environmental cause of dementia is E. coli toxin from cow manure contamination of the
groundwater. People with memory loss should consume only bottled or
professionally filtered water. No beef. The Center for Disease Control reports Escherichia coli (E. coli) bacteria normally live in the intestines of people and
animals. Most E. coli are harmless and actually are an important part of a healthy
human intestinal tract. However, some E. coli
are pathogenic, meaning they can cause illness, either diarrhea or illness
outside of the intestinal tract. The types of E. coli that can cause diarrhea can be transmitted through
contaminated water or food, or through contact with animals or persons. E. coli
consists of a diverse group of bacteria. Pathogenic E. coli strains are categorized
into pathotypes. Six pathotypes
are associated with diarrhea and collectively are referred to as diarrheagenic E. coli.
Shiga toxin-producing E. coli
(STEC)—STEC may also be referred to as Verocytotoxin
producing E. coli (VTEC) or enterohemorrhagic E.
coli (EHEC). This pathotype is the one most
commonly heard about in the news in association with foodborne outbreaks. The
other types are Enterotoxigenic E. coli (ETEC), Enteropathogenic E. coli (EPEC), Enteroaggregative
E. coli (EAEC), Enteroinvasive
E. coli (EIEC), and Diffusely
adherent E. coli (DAEC). The
infectivity or the virulence of an EHEC strain depends on several factors,
including the presence of fucose in the medium, the
sensing of this sugar and the activation of EHEC pathogenicity
island. Wikepedia elaborates a little
more on the Verocytotoxin E. coli (VTEC) listing enterohemorrhagic E.
coli (EHEC), hemolytic uremic syndrome (HUSEC), shiga
toxin producing E. coli (STEC), shigatoxinogenic E.
coli (STEC), shiga-like toxin producing E. coli (SLTEC), verotoxin-producing
E. coli (VTEC), veroxigenic
E. coli (VTEC) verocytotoxin-producing
E. coli (VTEC), verocytotoxigenic
E. coli (VTEC).
E. coli is a zoonotic infection most
commonly transmitted by the manure of cows (Bos taurus) that can cause food and
water-born epidemics in humans. Shiga toxin producing E. coli (STEC) seem to be more
associated with diarrhea so the water of forgetfulness is assumed to be
contaminated by verocytotoxin producing E. coli (VTEC). VTs produced by these
bacteria are thought to damage host endothelial cells in small vessels of the
intestine, kidney and brain resulting in thrombotic microangiopathy.
All VTs have the same subunit structure, glycolipid cell receptor and inhibit
protein synthesis. During VTEC infection, it is thought one or more bacterial adhesins initiates colonization and establishes intimate
attachment and is responsible for the translocation of a variety of effectors
which alter the
structure and function of host cells. VTEC are widespread in
animals but ruminants are thought to be their natural reservoir. E. coli O157:H7
colonizes the terminal colon of cattle and can be shed in very large numbers by
specific herd-mates known as "super-shedders". Feces containing these
organisms act as a source of contamination for a
variety of foods and the environment (Kamali
et al '09) in particular groundwater contaminated by watershed injection of
un-potable manure contaminated water. Beta-amyloid plaque
and/or tau in the brain of the Alzheimer's patient could be caused by Diffusely
adherent E. coli (DAEC).
Metronidazole is more helpful in the treatment of infectious diarrhea caused by
E. coli than Bactrim, but it is
contraindicated for use in central nervous system disease and when it comes to verocytotoxin contamination of the groundwater and memory
there is not really anything to do but stop drinking and cooking with cow
manure contaminated water.
Vasculitis and organophosphate poisoning each
occasionally cause a motor neuron disease. Jakob-Creutzfeldt
virus (JCV), most commonly presents as progressive dementia with seizures,
myoclonus, fasciculations and asymmetrical weakness
known as Mad Cow disease. (Wiederholt
Õ88: 191, 193). Mad Cow disease is a member of a family of
diseases called transmissible spongiform encephalopathies,
TSEs, seen in various animal species including humans, sheep, cows, mink, deer
and cats – for example, Creutzfeld-Jacob
Disease (CJD) in humans, scrapie in sheep, chronic
wasting syndrome in deer and elk, and bovine spongiform encephalopathy of BSE
in cows. They attack the central nervous system, causing disintegration
of the brain; they have a long incubation period (measured in years if not
decades) between the time
when infection first occurs and the appearance of
symptoms; they are always fatal; and they are transmitted by the eating of
animals or animal parts; especially brains and spinal cords. More than
167,000 British dairy cattle died between 1985 and 1995. In 2000 to 2001 between
4,700 and 9,800 French cattle had become infected with Mad Cow disease and up
to 100 of those had entered the human food chain. When it became clear
the disease had spread to Spain and Germany, the European Union called for the
destruction of up to another 2 million cattle. European beef consumption
plummeted. The infectious agent of Mad Cow disease remains infectious
even after exposure for an hour to a temperature of 680 degrees – enough
to melt lead – and can withstand antibiotics, boiling water, bleach,
formaldehyde and a variety of solvents, detergents, and enzymes known to
destroy most bacteria and viruses. The expected rate of occurrence of CJD
(the human variation of Mad Cow disease) has been 1 in 1 million people.
Yet one study found that people diagnosed with AlzheimerÕs disease, whose
symptoms were difficult to distinguish from CJD) were examined after death, 5.5
percent of the presumed AlzheimerÕs victims were found actually
to have CJD. Another study counted 13 percent (Robbins Õ01: 144, 145, 146,
149, 150). Organic food only, lots of green leafy
vegetables and no red meat.
Find concentrated animal feeding operations (CAFO) polluting the
watershed.